CLDX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.08M

-66.02%

-1.006

+41.7%

1.53M

+30.45%

-1.113

+37.45%

652.00K

-6.19%

-1.132

+33.14%

Estimates Revision

The market is revising Downward the revenue expectations for Celldex Therapeutics, Inc. (CLDX) for FY2025, with the revenue forecasts being adjusted by -20.67% over the past three months. During the same period, the stock price has changed by -0.69%.

Revenue Estimates for FY2025

Revise Downward

-20.67%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.97%

In Past 3 Month

Stock Price

Go Down

-0.69%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast CLDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLDX is 54.67 USD with a low forecast of 21.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

1 Sell

Strong Buy

Current: 0.000

Low

21.00

Averages

54.67

High

90.00

Current: 0.000

Low

21.00

Averages

54.67

High

90.00

Barclays

Equal Weight

maintain

$21 -> $24

2025-12-17

Reason

Barclays

Price Target

$21 -> $24

2025-12-17

maintain

Equal Weight

Reason

Barclays raised the firm's price target on Celldex to $24 from $21 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the biotechnology space as part of its 2026 outlook.

Barclays

Underweight

downgrade

$25 -> $21

2025-11-11

Reason

Barclays

Price Target

$25 -> $21

2025-11-11

downgrade

Underweight

Reason

Barclays lowered the firm's price target on Celldex to $21 from $25 and keeps an Underweight rating on the shares following the Q3 report.

Mizuho

Outperform

initiated

$48

2025-10-20

Reason

Mizuho

Price Target

$48

2025-10-20

initiated

Outperform

Reason

Mizuho initiated coverage of Celldex with an Outperform rating and $48 price target. The firm sees barzolvolimab as positioned to play a significant role in mast-cell mediated diseases, namely chronic urticaria. Mizuho added that it believes barzolvolimab has potential to establish best-in-class efficacy among the increasingly competitive landscape, offering the deepest and most sustained clinical benefit.

Wells Fargo

Overweight

downgrade

$44 -> $38

2025-08-20

Reason

Wells Fargo

Price Target

$44 -> $38

2025-08-20

downgrade

Overweight

Reason

Wells Fargo lowered the firm's price target on Celldex to $38 from $44 and keeps an Overweight rating on the shares. Shares should be down 10%-15% on the failure in eosinophilic esophagitis, but he Street was not assigning much to this program, the analyst tells investors in a research note. The firm would buy shares on weakness.

H.C. Wainwright

Buy

downgrade

$50 -> $42

2025-08-20

Reason

H.C. Wainwright

Price Target

$50 -> $42

2025-08-20

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Celldex to $42 from $50 and keeps a Buy rating on the shares. The company announced mixed topline results from its Phase 2 trial assessing barzolvolimab in eosinophilic esophagitis, the analyst tells investors in a research note. The firm removing eosinophilic esophagitis from its barzolvolimab projected indications.

Citi

Buy

downgrade

$56 -> $48

2025-08-20

Reason

Citi

Price Target

$56 -> $48

2025-08-20

downgrade

Buy

Reason

Citi lowered the firm's price target on Celldex to $48 from $56 and keeps a Buy rating on the shares. The company will not pursue barzolvolimab in eosinophilic esophagitis following the Phase 2 data, the analyst tells investors in a research note. Citi believes the shares were pricing in little to no value for this indication. Any selloff on the Phase 2 data will likely be temporary, the firm contends.

Valuation Metrics

The current forward P/E ratio for Celldex Therapeutics Inc (CLDX.O) is -6.13, compared to its 5-year average forward P/E of -13.29. For a more detailed relative valuation and DCF analysis to assess Celldex Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-13.29

Current PE

-6.13

Overvalued PE

-7.07

Undervalued PE

-19.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.41

Current EV/EBITDA

-4.54

Overvalued EV/EBITDA

1.24

Undervalued EV/EBITDA

-6.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

574.16

Current PS

500.11

Overvalued PS

849.42

Undervalued PS

298.90

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CLDX News & Events

Events Timeline

No data

News

8.0

2025-12-22NASDAQ.COM

Celldex Offers $25 Put Option, Attracting Investor Interest

9.0

2025-12-09Globenewswire

Celldex Initiates Global Phase 3 Trial for Cold Urticaria Treatment

9.0

2025-12-09Newsfilter

Celldex Initiates Global Phase 3 Trial for Barzolvolimab Efficacy in ColdU and SD

People Also Watch

Frequently Asked Questions

What is Celldex Therapeutics Inc (CLDX) stock price today?

The current price of CLDX is 27.35 USD — it has decreased -1.48 % in the last trading day.

What is Celldex Therapeutics Inc (CLDX)'s business?

Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.

What is the price predicton of CLDX Stock?

What is Celldex Therapeutics Inc (CLDX)'s revenue for the last quarter?

Celldex Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What is Celldex Therapeutics Inc (CLDX)'s earnings per share (EPS) for the last quarter?

Celldex Therapeutics Inc. EPS for the last quarter amounts to -1.01 USD, increased 57.81 % YoY.

What changes have occurred in the market's expectations for Celldex Therapeutics Inc (CLDX)'s fundamentals?

How many employees does Celldex Therapeutics Inc (CLDX). have?

Celldex Therapeutics Inc (CLDX) has 186 emplpoyees as of January 09 2026.

What is Celldex Therapeutics Inc (CLDX) market cap?

Today CLDX has the market capitalization of 1.82B USD.